English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduTwo experts from the Johns Hopkins Bloomberg School of Public Health are available for media interviews to discuss today’s announcement identifying the 10 drugs that will be subject to price negotiations under the Medicare program, as directed by the Centers…
Tag: drug prices
American College of Rheumatology Comments on 2023 Medicare Physician Fee Schedule & Quality Payment Program Rules
In comments submitted to the Centers for Medicare and Medicaid Services (CMS) in response to the CY 2023 Medicare Physician Fee Schedule and Quality Payment Program proposed rule, the ACR applauded proposals that would provide more flexibility and improve care coordination.
Rutgers Public Health Expert Available to Discuss the Impact of Allowing Medicare to Negotiate Drug Prices
Stephen Crystal, a distinguished research professor at Rutgers’ Institute for Health and School of Social Work who has spent decades studying the effect of public policy on health, is available to talk about the impact of allowing Medicare to negotiate…
How will the pending budget bill reduce drug prices for Americans?
The Inflation Reduction Act contains provisions that are expected to lower drug costs for millions of Americans by allowing Medicare to negotiate some drug prices and by limiting the amount of out-of-pocket drug costs for Medicare Part D patients.
Medicare could save up to $3.6 billion by purchasing generic drugs at Mark Cuban prices
A brief research report found that Medicare could have saved up to $3.6 billion by purchasing generic drugs at the same prices as the Mark Cuban Cost Plus Drug Company (MCCPDC) in 2020. These findings suggest that Medicare is overpaying for some generic drugs. The report is published in Annals of Internal Medicine.
Drug rebates for insurers tied to higher costs for patients, especially the uninsured
The study found that rebates were associated with increases in out-of-pocket costs for patients by an average of $6 for those with commercial insurance, $13 for Medicare patients and $39 for the uninsured.
Seven Medical Societies Join the ACR to Oppose Insurer Policy Limiting Access to In-Office Treatments
Providers are concerned the mandate adds an additional layer of red tape that will delay patient care, reduce the ability of providers to ensure therapies have been properly handled and safely stored, inflate patient out-of-pocket costs, and result in an increase of drug waste.
Has the Time Come for Pharma to Accept Modest Prices?
ISPOR, the professional society for health economics and outcomes research—explored the issue of drug pricing in the session, “Time for Change? Has the Time Come for the Pharma Industry to Accept Modest Prices?.”